Who is sponsoring NCT06237582?

NCT06237582 is sponsored by Jules Bordet Institute.

What drugs are being tested in NCT06237582?

Interventions in NCT06237582: epigastric lymph node biopsy.

What condition does NCT06237582 study?

NCT06237582 studies Carcinomatosis, Peritoneal.

Is NCT06237582 still recruiting?

NCT06237582 is currently completed. Last updated 1 February 2024.

Last reviewed 2024-02-01 · How we verify

NCT06237582: OvEpiLyPath

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases

Completed NA Last updated 1 February 2024

What this trial tests

NA trial testing epigastric lymph node biopsy in Carcinomatosis, Peritoneal in 20 participants. Completed in 30 September 2023.

Timeline

16 June 2022

Primary endpoint
1 January 2023

30 September 2023

Quick facts

Lead sponsor	Jules Bordet Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	16 June 2022
Primary completion	1 January 2023
Estimated completion	30 September 2023
Sites	1 location across Belgium

Drugs / interventions tested

epigastric lymph node biopsy

Conditions studied

Carcinomatosis, Peritoneal — all drugs for Carcinomatosis, Peritoneal →

Sponsor

Jules Bordet Institute

Who can join

18 and older, female only, with Carcinomatosis, Peritoneal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The IELN basin could represent a primary LN relay for systemic metastatic dissemination in patients with OPM. This newly described lymphatic pathway of metastatic dissemination of OPM may be involved in certain presentations of peritoneal dissemination. The presence of invaded IELN may represent a new biomarker predictive of the pattern of progression of OPM and a related risk for systemic dissemination.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

14<sup>th</sup> PSOGI-ISSPP International congress on Peritoneal Surface Malignancies*: Lyon, 26 - 28<sup>TH</sup> September 2024.
· 2024 · PMID 39944920 · DOI 10.1515/pp-2024-0031

Verify or expand the search:

Other Jules Bordet Institute trials

Trials by the same sponsor.

NCT07455331 — Flash Radiotherapy for Skin Cancer · Phase 2 · not yet recruiting
NCT07431346 — Prophylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy · NA · not yet recruiting
NCT06925984 — Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro- · NA · recruiting
NCT06523634 — Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy. · NA · recruiting
NCT06227338 — ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06237582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jules Bordet Institute
Last refreshed: 1 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06237582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing